Media coverage about Cascadian Therapeutics (NASDAQ:CASC) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cascadian Therapeutics earned a coverage optimism score of 0.15 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 44.4647499038177 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Separately, Zacks Investment Research lowered shares of Cascadian Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $5.63.

Cascadian Therapeutics (CASC) traded up $0.17 during trading hours on Thursday, reaching $4.22. 223,000 shares of the company were exchanged, compared to its average volume of 307,027. Cascadian Therapeutics has a 1-year low of $3.18 and a 1-year high of $4.97. The firm has a market cap of $211.85, a price-to-earnings ratio of -3.15 and a beta of 2.29.

Cascadian Therapeutics (NASDAQ:CASC) last issued its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.01. During the same quarter in the prior year, the company earned ($0.09) earnings per share. equities research analysts forecast that Cascadian Therapeutics will post -1.27 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Cascadian Therapeutics (CASC) Stock Price” was published by Daily Political and is the property of of Daily Political. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.dailypolitical.com/2018/01/18/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-cascadian-therapeutics-casc-stock-price.html.

About Cascadian Therapeutics

Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.

Insider Buying and Selling by Quarter for Cascadian Therapeutics (NASDAQ:CASC)

Receive News & Ratings for Cascadian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.